Ft Devens, MA – Bristol-Myers Squibb’s $750 million manufacturing plant in Ft Devens—the pharmaceutical company’s newest, biggest biologics facility and the largest capital investment in its history—is getting a 210ksf, $250 million addition. Two years of construction will start this fall.
BMS is doubling down on its investment here to accelerate the launch of new biologics therapies, an increasingly important part of the company’s pipeline according to BMS spokesman John Patella. The new project consists of a 110,000sf plant for pilot production of therapies used just before the company is ready to ramp up to commercial production on them and a 100,000sf plant to produce therapies for clinical trials.